{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:49:46Z","timestamp":1791974986067,"version":"4.4.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-21-039-01"],"award-info":[{"award-number":["RSG-21-039-01"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030717","name":"NCCN Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular disease (CVD) is the leading cause of noncancer mortality in long-term cancer survivors. Population-level assessment of cancer-related exposures is limited with respect to long-term cardiovascular risk in older survivors who have additional aging-related risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a Surveillance, Epidemiology, and End Results\u2013Medicare retrospective cohort study of long-term (5-year) survivors of breast, prostate, colon, and rectal cancers who were aged 66 years and older, diagnosed from 2003 to 2012, and received definitive treatment. The primary endpoint was late CVD, defined as myocardial infarction, stroke, congestive heart failure, or cardiomyopathy on an inpatient administrative claim or as Surveillance, Epidemiology, and End Results cause of death occurring 5-15\u2009years postdiagnosis. Restricted mean survival time regression was used to assess predictors of shorter average time without CVD and develop a prediction rule for risk stratification. Survivors were assigned a risk score and stratified into tertiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Included were 95\u2009100 survivors with a mean age of 74 (6) years at diagnosis. Late CVD occurred in 23.2% of survivors. Older age, comorbidities, and prior CVD were associated with a shorter time without CVD. In contrast, cancer-related factors were not associated, except for stage III breast cancer, and radiation plus androgen deprivation therapy for prostate cancer. Across all cohorts, the high-risk strata had a three- to fourfold higher risk of CVD compared with the low-risk strata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort of older, long-term cancer survivors, cancer-related exposures were not independently associated with onset of CVD 5-15\u2009years after diagnosis but may still contribute to latent cardiovascular risk. Given the limited impact of cancer-specific factors, cancer-agnostic risk prediction may be adequate to predict individual cardiovascular risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djaf243","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T11:23:13Z","timestamp":1756120993000},"page":"130-140","source":"Crossref","is-referenced-by-count":7,"title":["Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2060-2137","authenticated-orcid":false,"given":"Sarah J","family":"Westvold","sequence":"first","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B","family":"Long","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9825-1459","authenticated-orcid":false,"given":"Jane","family":"Fan","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-4348","authenticated-orcid":false,"given":"Madhav","family":"Kc","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3930-8876","authenticated-orcid":false,"given":"Terry","family":"Hyslop","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3436-5272","authenticated-orcid":false,"given":"Kerry","family":"Conlin","sequence":"additional","affiliation":[{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Yale College , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3339-6959","authenticated-orcid":false,"given":"Andrea","family":"Silber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-5784","authenticated-orcid":false,"given":"Shi-Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]},{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-7614","authenticated-orcid":false,"given":"Michael S","family":"Leapman","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]},{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health , New Haven, CT,","place":["United States"]},{"name":"Department of Urology, Yale University School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-8658","authenticated-orcid":false,"given":"Ira","family":"Leeds","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]},{"name":"Department of Surgery, Yale University School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-9330","authenticated-orcid":false,"given":"Lisa","family":"Spees","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center (UNC-CH) , Chapel Hill, NC,","place":["United States"]},{"name":"Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, UNC-CH , Chapel Hill, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3399-9047","authenticated-orcid":false,"given":"Stephanie B","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center (UNC-CH) , Chapel Hill, NC,","place":["United States"]},{"name":"Department of Health Policy and Management, Gillings School of Global Public Health, UNC-CH , Chapel Hill, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4974-935X","authenticated-orcid":false,"given":"Cary P","family":"Gross","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]},{"name":"Department of Internal Medicine, Yale University School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-7894","authenticated-orcid":false,"given":"Kevin","family":"Oeffinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University , Durham, NC,","place":["United States"]},{"name":"Duke Cancer Institute, Duke University , Durham, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4849-4743","authenticated-orcid":false,"given":"Michaela A","family":"Dinan","sequence":"additional","affiliation":[{"name":"Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center , New Haven, CT,","place":["United States"]},{"name":"Department of Chronic Disease Epidemiology, Yale School of Public Health , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"2026011207523670300_djaf243-B1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1055-9965.Epi-16-0133","article-title":"Anticipating the \u201cSilver Tsunami\u201d: prevalence trajectories and co-morbidity burden among older cancer survivors in the United States","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026011207523670300_djaf243-B2","doi-asserted-by":"publisher","first-page":"52:afad147","DOI":"10.1093\/ageing\/afad147","volume-title":"Age Ageing","author":"Pilleron","year":"2023"},{"key":"2026011207523670300_djaf243-B3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1055\/s-0042-1751234","article-title":"Epidemiology, pathophysiology, and management of coronary artery disease in the elderly","volume":"31","author":"Fadah","year":"2022","journal-title":"Int J Angiol"},{"key":"2026011207523670300_djaf243-B4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"2026011207523670300_djaf243-B5","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"New Engl J Med"},{"key":"2026011207523670300_djaf243-B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jncimonographs\/lgq002","article-title":"The interface between primary and oncology specialty care: treatment through survivorship","volume":"2010","author":"Grunfeld","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026011207523670300_djaf243-B7","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1002\/cncr.20560","article-title":"Under use of necessary care among cancer survivors","volume":"101","author":"Earle","year":"2004","journal-title":"Cancer"},{"key":"2026011207523670300_djaf243-B8","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1007\/s11606-009-1017-6","article-title":"Follow-up care delivery among colorectal cancer survivors most often seen by primary and subspecialty care physicians","volume":"24 Suppl 2","author":"Haggstrom","year":"2009","journal-title":"J Gen Intern Med"},{"key":"2026011207523670300_djaf243-B9","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw205","article-title":"Financial hardships experienced by cancer survivors: a systematic review","volume":"109","author":"Altice","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B10","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1002\/cncr.28262","article-title":"Are survivors who report cancer-related financial problems more likely to forgo or delay medical care?","volume":"119","author":"Kent","year":"2013","journal-title":"Cancer"},{"key":"2026011207523670300_djaf243-B11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/jnci\/djac036","article-title":"Workforce caring for cancer survivors in the United States: estimates and projections of use","volume":"114","author":"Mariotto","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jnci\/djy232","article-title":"Personalized risk-stratified cancer follow-up care: its potential for healthier survivors, happier clinicians, and lower costs","volume":"111","author":"Mayer","year":"2019","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1200\/OP.2023.19.11_suppl.331","article-title":"Loss to primary care provider follow-up among survivors five to seven years post-diagnosis","volume":"19","author":"Peluso","year":"2023","journal-title":"J Clin Oncol Oncol Pract"},{"key":"2026011207523670300_djaf243-B14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaccao.2022.03.005","article-title":"Cardiometabolic comorbidities in cancer survivors: JACC: CardioOncology State-of-the-Art review","volume":"4","author":"Zullig","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026011207523670300_djaf243-B15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jnci\/djy208","article-title":"Survivorship science at the NIH: lessons learned from grants funded in fiscal year 2016","volume":"111","author":"Rowland","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11764-014-0403-1","article-title":"The complex health profile of long-term cancer survivors: prevalence and predictors of comorbid conditions","volume":"9","author":"Leach","year":"2015","journal-title":"J Cancer Surviv"},{"key":"2026011207523670300_djaf243-B17","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"2026011207523670300_djaf243-B18","author":"Surveillance E; End Results Program (SEER)"},{"key":"2026011207523670300_djaf243-B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jncimonographs\/lgz029","article-title":"Updated overview of the SEER-Medicare Data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2026011207523670300_djaf243-B20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12874-021-01440-5","article-title":"Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review","volume":"21","author":"Bosco","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2026011207523670300_djaf243-B21","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1002\/sim.9495","article-title":"Restricted mean survival time regression model with time-dependent covariates","volume":"41","author":"Zhang","year":"2022","journal-title":"Stat Med"},{"key":"2026011207523670300_djaf243-B22","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-Sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Statist"},{"key":"2026011207523670300_djaf243-B23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circulation Research"},{"key":"2026011207523670300_djaf243-B24","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/jco.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026011207523670300_djaf243-B25","doi-asserted-by":"publisher","first-page":"10011","DOI":"10.1200\/JClinOncol.2017.35.15_suppl.10011","article-title":"New-onset congestive heart failure (CHF) and cardiovascular disease (CVD) in older colorectal cancer (CRC) survivors: a population-based study","volume":"35","author":"Kenzik","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026011207523670300_djaf243-B26","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1200\/jco.2005.02.5841","article-title":"Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study","volume":"23","author":"Doyle","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026011207523670300_djaf243-B27","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026011207523670300_djaf243-B28","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/jnci\/djae107","article-title":"Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors","volume":"116","author":"Vo","year":"2024","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/jnci\/djaa096","article-title":"All-cause and cardiovascular disease mortality among breast cancer survivors in CLUE II, a long-standing community-based cohort","volume":"113","author":"Ramin","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/jco.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026011207523670300_djaf243-B32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.eururo.2018.12.032","article-title":"Surgery versus radiation for high-risk prostate cancer: the fight continues. But is it time to call a draw and reach consensus?","volume":"75","author":"Sooriakumaran","year":"2019","journal-title":"Eur Urol"},{"key":"2026011207523670300_djaf243-B33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41391-020-00291-3","article-title":"Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients","volume":"24","author":"Miccio","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026011207523670300_djaf243-B34","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/jnci\/dji067","article-title":"Risk of cardiac death after adjuvant radiotherapy for breast cancer","volume":"97","author":"Giordano","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40959-021-00101-2","article-title":"Etiology and management of hypertension in patients with cancer","volume":"7","author":"Mohammed","year":"2021","journal-title":"Cardio-Oncol"},{"key":"2026011207523670300_djaf243-B36","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/HYP.0000000000000224","article-title":"Cancer therapy\u2013related hypertension: a scientific statement from the American Heart Association","volume":"80","author":"Cohen","year":"2023","journal-title":"Hypertension"},{"key":"2026011207523670300_djaf243-B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2021.02.003","article-title":"Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease","volume":"87","author":"Whelton","year":"2021","journal-title":"Eur J Int Med."},{"key":"2026011207523670300_djaf243-B38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1111\/j.1532-5415.2006.00973.x","article-title":"Multimorbidity and survival in older persons with colorectal cancer","volume":"54","author":"Gross","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"2026011207523670300_djaf243-B39","doi-asserted-by":"publisher","first-page":"107796","DOI":"10.1016\/j.ypmed.2023.107796","article-title":"Cardiovascular-specific mortality and risk factors in colorectal cancer patients: a cohort study based on registry data of over 500,000 individuals in the US","volume":"179","author":"Zhang","year":"2024","journal-title":"Prev Med"},{"key":"2026011207523670300_djaf243-B40","doi-asserted-by":"publisher","first-page":"djv402","DOI":"10.1093\/jnci\/djv402","article-title":"Incidence of diabetes in colorectal cancer survivors","volume":"108","author":"Singh","year":"2016","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B41","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/jco.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026011207523670300_djaf243-B42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026011207523670300_djaf243-B43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1200\/JClinOncol.2024.42.4_suppl.296","article-title":"Weight variation during androgen deprivation therapy in patients with localized prostate cancer: data from two prospective randomized trials","volume":"42","author":"Nabid","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djaf243\/64603818\/djaf243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/1\/130\/64603818\/djaf243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/118\/1\/130\/64603818\/djaf243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:52:44Z","timestamp":1768222364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/118\/1\/130\/8280240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djaf243","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,9]]}}}